Clinical Trials Browser

Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT01857193 2021-04-13

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Phase 1 Completed

132 enrolled

Breast

Breast Neoplasms

NCT02392611 2020-12-29

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

Phase 1 Completed

33 enrolled 23 charts

Lymphoid

Lymphoma

NCT02077933 2020-12-08

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Phase 1 Completed

79 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

NCT01597193 2019-05-08

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

Phase 1 Completed

101 enrolled 33 charts

Breast

Breast Neoplasms

NCT02833155 2019-05-07

Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer

Phase 1 Completed

19 enrolled

Breast

Breast Neoplasms

NCT01938846 2019-01-04

BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors

Phase 1 Completed

90 enrolled 22 charts

Tumor-Agnostic

Neoplasms

Clinical Trials

PIKASSO-01

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Sapu003 in Advanced mTOR-sensitive Solid Tumors

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

ENCORE110

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer

BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors